Literature DB >> 16287839

The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3.

Luke F Peterson1, Anita Boyapati, Velvizhi Ranganathan, Atsushi Iwama, Daniel G Tenen, Schickwann Tsai, Dong-Er Zhang.   

Abstract

The family of cyclin D proteins plays a crucial role in the early events of the mammalian cell cycle. Recent studies have revealed the involvement of AML1 transactivation activity in promoting cell cycle progression through the induction of cyclin D proteins. This information in combination with our previous observation that a region in AML1 between amino acids 213 and 289 is important for its function led us to investigate prospective proteins associating with this region. We identified cyclin D3 by a yeast two-hybrid screen and detected AML1 interaction with the cyclin D family by both in vitro pull-down and in vivo coimmunoprecipitation assays. Furthermore, we demonstrate that cyclin D3 negatively regulates the transactivation activity of AML1 in a dose-dependent manner by competing with CBFbeta for AML1 association, leading to a decreased binding affinity of AML1 for its target DNA sequence. AML1 and its fusion protein AML1-ETO have been shown to shorten and prolong the mammalian cell cycle, respectively. In addition, AML1 promotes myeloid cell differentiation. Thus, our observations suggest that the direct association of cyclin D3 with AML1 functions as a putative feedback mechanism to regulate cell cycle progression and differentiation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16287839      PMCID: PMC1291252          DOI: 10.1128/MCB.25.23.10205-10219.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  57 in total

1.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.

Authors:  E Neuman; M H Ladha; N Lin; T M Upton; S J Miller; J DiRenzo; R G Pestell; P W Hinds; S F Dowdy; M Brown; M E Ewen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle.

Authors:  D K Strom; J Nip; J J Westendorf; B Linggi; B Lutterbach; J R Downing; N Lenny; S W Hiebert
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

Review 3.  Transcription factors, normal myeloid development, and leukemia.

Authors:  D G Tenen; R Hromas; J D Licht; D E Zhang
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

4.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

5.  Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model.

Authors:  K L Rhoades; C J Hetherington; N Harakawa; D A Yergeau; L Zhou; L Q Liu; M T Little; D G Tenen; D E Zhang
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

Review 6.  Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation.

Authors:  B Lutterbach; S W Hiebert
Journal:  Gene       Date:  2000-03-21       Impact factor: 3.688

7.  Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins.

Authors:  J Lou; W Cao; F Bernardin; K Ayyanathan; F J RauscherIII; A D Friedman
Journal:  Oncogene       Date:  2000-05-18       Impact factor: 9.867

8.  Sustained activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells.

Authors:  F K Racke; K Lewandowska; S Goueli; A N Goldfarb
Journal:  J Biol Chem       Date:  1997-09-12       Impact factor: 5.157

9.  The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2.

Authors:  M Kitagawa; H Higashi; H K Jung; I Suzuki-Takahashi; M Ikeda; K Tamai; J Kato; K Segawa; E Yoshida; S Nishimura; Y Taya
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

10.  Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress RUNX (CBF(alpha)/AML/PEBP2(alpha)) dependent activation of tissue-specific gene transcription.

Authors:  A Javed; B Guo; S Hiebert; J Y Choi; J Green; S C Zhao; M A Osborne; S Stifani; J L Stein; J B Lian; A J van Wijnen; G S Stein
Journal:  J Cell Sci       Date:  2000-06       Impact factor: 5.285

View more
  27 in total

1.  The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes.

Authors:  Rachit Bakshi; Mohammad Q Hassan; Jitesh Pratap; Jane B Lian; Martin A Montecino; Andre J van Wijnen; Janet L Stein; Anthony N Imbalzano; Gary S Stein
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

Review 2.  Blood and immune cell engineering: Cytoskeletal contractility and nuclear rheology impact cell lineage and localization: Biophysical regulation of hematopoietic differentiation and trafficking.

Authors:  Jae-Won Shin; Dennis E Discher
Journal:  Bioessays       Date:  2015-03-23       Impact factor: 4.345

3.  AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex.

Authors:  Joseph R Biggs; Luke F Peterson; Youhong Zhang; Andrew S Kraft; Dong-Er Zhang
Journal:  Mol Cell Biol       Date:  2006-08-05       Impact factor: 4.272

Review 4.  Cell cycle and developmental control of hematopoiesis by Runx1.

Authors:  Alan D Friedman
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

5.  Runx1 exon 6-related alternative splicing isoforms differentially regulate hematopoiesis in mice.

Authors:  Yukiko Komeno; Ming Yan; Shinobu Matsuura; Kentson Lam; Miao-Chia Lo; Yi-Jou Huang; Daniel G Tenen; James R Downing; Dong-Er Zhang
Journal:  Blood       Date:  2014-04-25       Impact factor: 22.113

6.  Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.

Authors:  Eun-Young Ahn; Ming Yan; Oxana A Malakhova; Miao-Chia Lo; Anita Boyapati; Hans Beier Ommen; Robert Hines; Peter Hokland; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

7.  Quantitative trait loci for porcine baseline erythroid traits at three growth ages in a White Duroc x Erhualian F(2) resource population.

Authors:  Zhengzhi Zou; Jun Ren; Xueming Yan; Xiang Huang; Shujin Yang; Zhiyan Zhang; Bin Yang; Wanbo Li; Lusheng Huang
Journal:  Mamm Genome       Date:  2008-10-15       Impact factor: 2.957

8.  The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.

Authors:  Luke F Peterson; Ming Yan; Dong-Er Zhang
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

Review 9.  Post-translational modifications of Runx1 regulate its activity in the cell.

Authors:  Lan Wang; Gang Huang; Xinyang Zhao; Megan A Hatlen; Ly Vu; Fan Liu; Stephen D Nimer
Journal:  Blood Cells Mol Dis       Date:  2009-04-21       Impact factor: 3.039

10.  Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation.

Authors:  Linsheng Zhang; Florence B Fried; Hong Guo; Alan D Friedman
Journal:  Blood       Date:  2007-11-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.